Final version of 2009 AJCC melanoma staging and classification.

By C. Balch, J. Gershenwald, S. Soong, John F. Thompson, M. Atkins, D. Byrd, A. Buzaid, A. Cochran, D. Coit, Shouluan Ding and 10 more. Journal of Clinical Oncology, 2009

4,641 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0eb929711868cf08f7b877d40409eccfe18aec75

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

Chunhua Shen

In Molecular Biology

In Oncology

Citations in the corpus

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (2015, background): “The primary analysis included patients with poor prognostic factors for OS in stage IV melanoma, such as elevated serum lactate dehydrogenase levels and brain metastases at baseline.(21) In both phase III trials of ipilimumab in advanced melanoma, more than one third of patients had elevated serum l”
Automatic Skin Lesion Segmentation Using Deep Fully Convolutional Networks With Jaccard Distance (2017, background): “Nowadays, despite the fact that some advanced treatment techniques, such as radiation therapy and immunotherapy, are increasingly combined with surgery in clinical practice [2], the five year survival rate for advanced stage melanoma is still as low as 15% while it is over 95% for early-stage melano”
A Mutual Bootstrapping Model for Automated Skin Lesion Segmentation and Classification (2019, background): “SKIN cancer is one of the most common malignancies to affect the elderly worldwide [1], [2].”
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab (2016, methodology): “Baseline patient characteristics were collected, including age, sex and prognostic factors [7th edition of the American Joint Committee on Cancer (AJCC) pathologic stage [13], presence of brain metastases, serum lactate dehydrogenase level and Eastern Cooperative Oncology Group Performance Status (E”
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, methodology): “The histology report should follow the American Joint Committee on Cancer (AJCC) classification [8], and include: information on the maximum thickness in millimetres (Breslow), information on mitotic rate in case of a tumour thickness below 1 mm, presence of ulceration, presence and extent of regres”
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011, background): “Durable complete regressions using dacarbazine, the only other FDA-approved treatment for melanoma, is seen in less than 1% of patients (1, 2).”
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (2016, background): “The population of patients with stage III melanoma is heterogeneous, with disease-specific survival rates of 78% among patients with stage IIIA disease, 59% among those with stage IIIB disease, and 40% among those with stage IIIC disease.(5-7) Even within the population of patients who have sentinel”
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011, background): “The 1-year survival rate for patients with American Joint Committee on Cancer (AJCC) stage IV visceral metastatic melanoma is 33% (1).”
NRAS Mutation Status is an Independent Prognostic Factor in Metastatic Melanoma (2011, methodology): “c According to the American Joint Committee on Cancer AJCC Cancer Staging Manual, 7th edition.(4) d BRAF vs NRAS, P 1⁄4 .”
Genomic Classification of Cutaneous Melanoma (2015, background): “Overall, survival has historically been poor for patients with distant metastatic disease, and response to conventional chemotherapy has been infrequent (Balch et al., 2009).”